CN109453280A - A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases - Google Patents
A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases Download PDFInfo
- Publication number
- CN109453280A CN109453280A CN201910017614.3A CN201910017614A CN109453280A CN 109453280 A CN109453280 A CN 109453280A CN 201910017614 A CN201910017614 A CN 201910017614A CN 109453280 A CN109453280 A CN 109453280A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- weight
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to field of medicaments, and in particular to a kind of application of Chinese medicine composition in the drug for being used to prepare treatment mucosa injury associated diseases.The Traditional Chinese medicine composition formula is as follows: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis, 120 parts by weight of the root of Dahurain angelica, 120 parts by weight of Poria cocos, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 0.4 parts by volume of 10 parts by weight of extract of licorice root, 0.8 parts by volume of patchouli oil and perilla leaf oil.Chinese medicine composition of the invention uses traditional Chinese medicine for raw material, and toxic side effect is small, peomotes the proliferation of mucomembranous cell, and the reparation for damaging mucous membrane has facilitation.Therefore, Chinese medicine composition of the invention can be used for preparing the drug for the treatment of mucosa injury associated diseases.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of Chinese medicine composition is being used to prepare disease caused by treatment mucosa injury
Application in the drug of disease.
Background technique
Mucosa injury is relatively conventional in life.Infectious diseases, allergic disease, local stimulation etc. can make
At oral mucosa lesion；Chemical factor (smokes, drinks, drinking tea, coffee and irritating drug such as aspirin, indocin
Deng), physical factor (supercooling, excessively boiling hot, excessively coarse food or overeating etc.), bacterium or its toxin the factors such as stimulate
It can cause gastric mucosa damage；The factors such as constipation may cause intestinal tract injury.
It there is no the method for the reparation mucosa injury of good result at present.
Granted patent CN200910260975.7 discloses a kind of for treating gastritis and gastric ulcer, the system for protecting gastric mucosa
Agent uses Radix Astragali, Rhizoma Atractylodis Macrocephalae, dandelion, evodia rutaecarpa, the root of Dahurain angelica, bletilla for raw material, it is characterised in that it is matched by following weight
Raw material made of preparation: with Radix Astragali 520-580g, Rhizoma Atractylodis Macrocephalae 290-350g, dandelion 250-310g, evodia rutaecarpa 220-280g, white
Root of Dahurian angelica 170-230g, bletilla 40-80g are raw material, and the techniques such as extracted, concentration, crushing, mixing obtain fine powder, in conjunction with pharmaceutic adjuvant
Different dosage forms, such as capsule, tablet, granule is made.The invention only demonstrates the effect of superficial gastritis, main function
It is the secretion of gastric acid inhibitory and mitigates gastritis symptom, does not verify whether that there is repairing effect to gastric mucosa.
Therefore a kind of application of Chinese medicine composition in the drug for being used to prepare treatment mucosa injury associated diseases is developed.
Summary of the invention
In view of this, the purpose of the present invention is to provide a kind of Chinese medicine compositions caused by being used to prepare treatment mucosa injury
Application in the drug of disease.
To achieve the above object, the technical solution of the present invention is as follows:
A kind of application of Chinese medicine composition in the drug of preparation treatment mucosa injury associated diseases, which is characterized in that institute
It is as follows to state Traditional Chinese medicine composition formula: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis, 120 parts by weight of the root of Dahurain angelica, Fu
120 parts by weight of Siberian cocklebur, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 10 parts by weight of extract of licorice root, 0.8 parts by volume of patchouli oil
With 0.4 parts by volume of perilla leaf oil.
Preferably, the preparation method of the Chinese medicine composition includes the following steps: the Cortex Magnoliae Officinalis ethyl alcohol for taking formula ratio
Refluxing extraction obtains the ethanol extract of Cortex Magnoliae Officinalis；The rhizoma atractylodis, the dried orange peel and the root of Dahurain angelica of formula ratio are steamed with water as medium
Extraction is evaporated, must distill and extract mixed liquor；The shell of areca nut water of the formula ratio is decocted and filtered, shell of areca nut decoction liquor is obtained；It will
After the Poria cocos of the formula ratio is boiled with water as medium, and 70-90 DEG C is cooled to sufficiently infiltrating and filtering, obtain the leaching of Poria cocos temperature
Liquid；It takes the dried pinellia of formula ratio sufficiently to be impregnated with aqueous medium, obtains tuber of pinellia soak；And it takes and is equivalent to dried pinellia weight ratio 0.06-
0.1 times of rhizoma zingiberis, decocts again, obtains the tuber of pinellia and rhizoma zingiberis obtains mixed soaking solution；
Mixed liquor, shell of areca nut decoction liquor, the immersion liquid of Poria cocos temperature and the tuber of pinellia are extracted into the ethanol extract, distillation and done
Ginger obtains mixed soaking solution and is sufficiently mixed, and is concentrated into density and is the paste of 1.10-1.20, and the Radix Glycyrrhizae leaching of formula ratio is added
The paste is mixed with the extract of licorice root and is recycled ethyl alcohol, the wide leaves of pulse plants of auxiliary material Tween 80 and the formula ratio is added by cream
The aqueous medium of sesame oil, the mixed liquor of perilla leaf oil and surplus adjusts pH value to 5.8-6.2 with sodium hydroxide, obtains the Chinese medicine group
Close object.
Chinese medicine composition of the invention is for can directly give in the form of a solution, can also prepare as needed when treating
Any pharmaceutically acceptable dosage form.The pharmaceutically acceptable dosage form include Chinese medicine composition of the invention and it is optional a kind of or
A variety of pharmaceutically acceptable carriers, diluent or excipient and the addition of suitable step in above-mentioned preparation process.The present invention
Used term " pharmaceutically acceptable " refers to such compound, raw material, composition and/or dosage form, they are reasonable
In the range of medical judgment, be suitable for contacted with patient tissue and without excessive toxicity, irritation, allergy or with reasonable benefit
The symmetrical other problems of benefit/Hazard ratio and complication, and effective for given application.
Pharmaceutical preparation is suitable for being administered by any suitable approach, for example, by take orally (including oral cavity or sublingual), rectum,
Nose, part (including oral cavity, sublingual or percutaneous), vagina or parenteral (including subcutaneous, intradermal, intramuscular, intra-articular, intrasynovial, chest
Bone is interior, intrathecal, intralesional, intravenous or intradermal injection or infusion) approach.It can be by any known method of art of pharmacy
This kind of preparation is prepared, such as by mixing active constituent with carrier or excipient.It is preferred that oral administration, local administration or injection
Administration.
Pharmaceutical preparation suitable for oral administration is provided by independent unit, such as the solution in aqueous or non-aqueous liquid
Or suspension；Capsule or tablet；Powder or granule；Edible foam formulations or foaming preparations etc..
For example, for oral administration in the form of a tablet or capsule, active medicine component can with can pharmaceutically connect
The oral, non-toxic inert carrier (such as ethyl alcohol, glycerol, water etc.) received mixes.By the way that compound powder is broken into suitable fine ruler
It is very little, and mix with the pharmaceutical carrier (such as the edible carbohydrate such as starch or mannitol) equally crushed to prepare powder.Also
Corrigent, preservative, dispersing agent and colorant may be present.
It by preparing pulverulent mixture as described above, and is loaded into the gelatin shell of forming, to prepare capsule.It is filling
It fills out before operation, it can be by glidant and lubricant (such as colloidal silicon dioxide, talcum powder, magnesium stearate, calcium stearate or solid-state
Polyethylene glycol) it is added in pulverulent mixture.Can also be added when taking capsule by improve drug utilizability disintegrating agent or
Solubilizer (such as agar, calcium carbonate or sodium carbonate).
When furthermore needing or is required, suitable adhesive, lubricant, disintegrating agent and colorant can also be mixed mixture
In.Suitable adhesive includes starch, gelatin, natural sugar (such as glucose or beta lactose), corn sweetener, natural and synthesis
Gummy (such as gum arabic, tragacanth or mosanom), carboxymethyl cellulose, polyethylene glycol etc..For these dosage forms
Lubricant includes enuatrol, sodium chloride etc..Disintegrating agent includes but is not limited to starch, methylcellulose, agar, bentonite, xanthan
Glue etc..For example, lubricant and disintegrating agent is added by the way that pulverulent mixture, granulation or pre- tabletting is made, and it is tabletted, to make
At tablet.By the compound suitably crushed and diluent as described above or base-material, optionally with adhesive, (such as carboxymethyl is fine
Tie up element, alginates, gelatin or polyvinylpyrrolidone), dissolve inhibitor (such as paraffin), absorbsion accelerator (quaternary salt) and/or
Absorbent (such as bentonite, kaolin or Dicalcium Phosphate) mixing, to prepare pulverulent mixture.Useful binders (such as syrup, shallow lake
Slurry, mucialga of arabic gummy or cellulosic material or polymeric material solution) wetting after pressurize sieving, pulverulent mixture is pelletized.System
One alternative of grain is can be made by pulverulent mixture by tablet press machine the result is that will form bad agglomerate and smash again
Particle.Can be by the way that stearic acid, stearate be added, talcum powder or mineral oil make particle lubrication to prevent from adhering to the punch die of tablet press machine
On.Then the mixture through lubricating is tabletted.The compound of the content of present invention can also be mixed with the inert carrier of free-flowing
It closes, it can be tabletted without passing through granulation or pre- tableting step.It can provide transparent or opaque by shellac seal coat, sugar-coat
Or the protectiveness coating material of polymeric material clothing and wax polishing clothing composition.Dyestuff can be added in these coating materials to distinguish
Different unit doses.
Oral liquid such as solution, syrup and elixir can be prepared with dosage unit form, so that specified rate contains
There is the compound of predetermined amount.Syrup can be prepared by the way that compound to be dissolved in suitably seasoned aqueous solution, and elixir can lead to
It crosses using non-toxic vehicle and prepares.Can also be added preservative, flavoring additive (such as peppermint oil or natural sweetener or saccharin or
Other artificial sweeteners) etc..
Pharmaceutical preparation suitable for percutaneous dosing can be used as discrete patch to keep close with recipient's epidermis in a long time
Cut-grafting touching.For example, active constituent can be by passing medicine by electro-ionic osmosis patch, usually reference can be made to Pharmaceutical
Research1986,3(6),318。
Pharmaceutical preparation suitable for local administration can be made into ointment, cream, suspension, lotion, powder, solution, paste
Agent, gelling agent, spray, aerosol, oil formulation or transdermal patch.
Pharmaceutical preparation (wherein carrier is solid) suitable for nose administration includes that partial size is such as 20-500 micron range
Dust base is quickly sucked from the coarse powder agent container close to nose by being administered in a manner of snuffing by nasal passage.Wherein carry
Body is liquid, is suitable for aqueous solution agent or oil that the appropriate formulation that nasal mist or nasal drop are administered includes active constituent
Property solution.
Include minuteness particle pulvis or mist agent suitable for the pharmaceutical preparation by inhalation, can be measured with different type
Dosage compresed gas aerosol, nebulizer, insufflator or other matters delivering aerosol spray device in prepare.
Pharmaceutical preparation suitable for parenteral includes water-based and non-aqueous sterile injection solution and aqueous and non-aqueous
Sterile suspensions, water-based and non-aqueous sterile injection solution can contain antioxidant, buffer, bacteriostatic agent and make the preparation
The isotonic solute with receptor's blood waiting.Preparation can be provided with unit dose or multi-dose container, such as the peace of sealing is triumphant and small
Bottle, and can be reserved under the conditions of freeze-drying (freeze-drying), only sterile liquid carrier, such as water for injection need to be added before use.
The injection solution for facing used time configuration can be prepared by sterile powder injection, granule and tablet.
Pharmaceutical preparation can be in unit dosage forms, and each unit dose contains the active constituent of predetermined amount.Dose regimen can be used as growing
Phase or short-term therapy.Mixing with carrier material will be according to disease to be treated, disease to prepare the amount of the active constituent of single formulation
Disease severity, administration time, administration route, the discharge rate of compound used therefor, treatment time and patient age, gender,
Weight and situation and change.Preferred unit dosage forms are the daily dose containing above-mentioned active constituent or divided dose or its appropriate fraction
Unit dosage forms.It can start to treat with the low dose of already clearly below compound optimal dose.Hereafter, it is increased with lesser increment
Dosage until reaching optimum efficiency in this case.In general, the concentration level for most desirably giving compound is usual
Effective result can be provided without regard to causing any harmful or toxic side effect in anti-virus aspect.
When composition of the invention can also be with the combination of one or more other treatment drugs or prophylactic agent, compound
Dosage level with other drug is usually in monotherapy scheme, the about 10-150% of Zhan Zhengchang dosage, more preferably
Account for the about 10-80% of normal dosage.
Preferably, the mucous membrane includes gastric mucosa, oral mucosa or Colon and rectum mucous membrane.
Preferably, the disease is stomatitis or canker sore caused by oral mucosa lesion, gastritis caused by gastric mucosa damage,
Rotten to the corn or ulcer, colitis caused by Colon and rectum mucosa injury.
Preferably, the disease is that mucosa injury is pain caused.
Preferably, the disease is skin lesion pain or bleeding caused by mucosa injury.
The beneficial effects of the present invention are: Chinese medicine composition provided by the invention uses traditional Chinese medicine for raw material, and poison is secondary to be made
With small, facilitate the proliferation of mucomembranous cell, can be used for preparing the drug for the treatment of mucosa injury.Chinese medicine composition of the invention can
Shorten the cure time of mucosa injury, accelerates cell migration, patient is allowed to walk out disease shade as early as possible, it is strong beneficial to the body and mind of patient
Health.
Specific embodiment
It detailed description of a preferred embodiment of the present invention will be given below.The reality of actual conditions is not specified in preferred embodiment
Proved recipe method, usually according to normal condition, illustrated embodiment are but not to be to preferably be illustrated to the contents of the present invention
The contents of the present invention are only limitted to illustrated embodiment.So those skilled in the art are according to foregoing invention content to embodiment party
Case carries out nonessential modifications and adaptations, still falls within protection scope of the present invention.
Embodiment 1
Rhizoma atractylodis 80g, dried orange peel 80g, Cortex Magnoliae Officinalis (ginger system) 80g, root of Dahurain angelica 120g, Poria cocos 120g, shell of areca nut 120g, dried pinellia 80g,
Extract of licorice root 10g, patchouli oil 0.8ml, perilla leaf oil 0.4ml.
It takes the Cortex Magnoliae Officinalis of formula ratio to be extracted with alcohol reflux, obtains the ethanol extract of Cortex Magnoliae Officinalis；By the described grey of formula ratio
Art, the dried orange peel and the root of Dahurain angelica are distilled with water as medium to be extracted, and must be distilled and be extracted mixed liquor；By the shell of areca nut of the formula ratio
It is decocted and is filtered with water, obtain shell of areca nut decoction liquor；After the Poria cocos of the formula ratio is boiled with water as medium, and it is cooled to 70-
90 DEG C, to sufficiently infiltrating and filtering, obtain Poria cocos temperature immersion liquid；It takes the dried pinellia of formula ratio sufficiently to be impregnated with aqueous medium, obtains tuber of pinellia immersion
Liquid；And the rhizoma zingiberis for being equivalent to 0.06-0.1 times of dried pinellia weight ratio is taken, it decocts again, obtains the tuber of pinellia and rhizoma zingiberis obtains mixed soaking solution；
Mixed liquor, shell of areca nut decoction liquor, the immersion liquid of Poria cocos temperature and the tuber of pinellia are extracted into the ethanol extract, distillation and done
Ginger obtains mixed soaking solution and is sufficiently mixed, and is concentrated into density and is the paste of 1.10-1.20, and the Radix Glycyrrhizae leaching of formula ratio is added
The paste is mixed with the extract of licorice root and is recycled ethyl alcohol, the wide leaves of pulse plants of auxiliary material Tween 80 and the formula ratio is added by cream
The mixed liquor of sesame oil, perilla leaf oil adds water to 1025ml, adjusts pH to 5.8-6.2, stands, filters to obtain clear solution, sterilizes,
It is filling to obtain solution.
1 human gastric epithelial cell line GES-1 of experimental example
1. experimental procedure
The solution that embodiment 1 obtains is added when disk being divided to carry out secondary culture, in 1 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.05ml/1ml culture medium；The solution that embodiment 1 obtains is added in 2 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.025ml/1ml culture medium；Ultrapure water is added in control group culture solution, additional amount is 0.05ml/1ml culture
Base.Above-mentioned three kinds of culture mediums are used to cultivate human gastric epithelial cell line GES-1 cell, are observed before culture and after culture 2 days
The growing state of cell, and counting of taking pictures.
2. experimental result
The growth of the cell number of experimental group 1 and experimental group 2 is significantly higher than control group, therefore, pharmaceutical composition of the invention
Play the role of promoting human gastric epithelial cell line GES-1 cell Proliferation.
2 people of experimental example normal Colon and rectum mucomembranous cell system FHC
1. experimental procedure
The solution that embodiment 1 obtains is added when disk being divided to carry out secondary culture, in 1 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.05ml/1ml culture medium；The solution that embodiment 1 obtains is added in 2 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.025ml/1ml culture medium；Ultrapure water is added in control group culture solution, additional amount is 0.05ml/1ml culture
Base.Above-mentioned three kinds of culture mediums are used to cultivate people's normal Colon and rectum mucomembranous cell system FHC cell, the growth of cell is observed after 2 days
Situation, and counting of taking pictures.
2. experimental result
| Group | Cell number increases (%) |
| Experimental group 1 | 75 |
| Experimental group 2 | 70 |
| Control group | 50 |
The growth of the cell number of experimental group 1 and experimental group 2 is significantly higher than control group, therefore, pharmaceutical composition of the invention
Play the role of promoting people's normal Colon and rectum mucomembranous cell system FHC cell Proliferation.
The normal human oral mucosa's fibroblast HOMF of experimental example 3
1. experimental procedure
The solution that embodiment 1 obtains is added when disk being divided to carry out secondary culture, in 1 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.05ml/1ml culture medium；The solution that embodiment 1 obtains is added in 2 culture solution of experimental group (to be already expired and filter out
Bacterium), additional amount is 0.025ml/1ml culture medium；Ultrapure water is added in control group culture solution, additional amount is 0.05ml/1ml culture
Base.Above-mentioned three kinds of culture mediums are used to cultivate normal human oral mucosa's fibroblast HOMF cell, cell is observed after 2 days
Growing state, and counting of taking pictures.
2. experimental result
| Group | Cell number increases (%) |
| Experimental group 1 | 90 |
| Experimental group 2 | 80 |
| Control group | 60 |
The growth of the cell number of experimental group 1 and experimental group 2 is significantly higher than control group, therefore, pharmaceutical composition of the invention
Play the role of promoting normal human oral mucosa's fibroblast HOMF cell Proliferation.
Finally, it is stated that the above examples are only used to illustrate the technical scheme of the present invention and are not limiting, although referring to compared with
Good embodiment describes the invention in detail, those skilled in the art should understand that, it can be to skill of the invention
Art scheme is modified or replaced equivalently, and without departing from the objective and range of technical solution of the present invention, should all be covered at this
In the scope of the claims of invention.
Claims (9)
1. a kind of application of Chinese medicine composition in the drug of preparation treatment mucosa injury associated diseases, which is characterized in that described
Traditional Chinese medicine composition formula is as follows: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis, 120 parts by weight of the root of Dahurain angelica, Poria cocos
120 parts by weight, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 10 parts by weight of extract of licorice root, 0.8 parts by volume of patchouli oil and
0.4 parts by volume of perilla leaf oil.
2. application of the Chinese medicine composition as described in claim 1 in the drug of preparation treatment mucosa injury associated diseases, special
Sign is that the preparation method of the Chinese medicine composition includes the following steps: to take the Cortex Magnoliae Officinalis of formula ratio to be extracted with alcohol reflux,
Obtain the ethanol extract of Cortex Magnoliae Officinalis；The rhizoma atractylodis, the dried orange peel and the root of Dahurain angelica of formula ratio are distilled with water as medium and are extracted, are obtained
Mixed liquor is extracted in distillation；The shell of areca nut water of the formula ratio is decocted and filtered, shell of areca nut decoction liquor is obtained；By the formula ratio
Poria cocos boiled with water as medium after, and be cooled to 70-90 DEG C to sufficiently infiltrating and filtering, obtain Poria cocos temperature immersion liquid；Take formula ratio
Dried pinellia sufficiently impregnated with aqueous medium, obtain tuber of pinellia soak；And the rhizoma zingiberis for being equivalent to 0.06-0.1 times of dried pinellia weight ratio is taken,
It decocts again, obtains the tuber of pinellia and rhizoma zingiberis obtains mixed soaking solution；
Mixed liquor, shell of areca nut decoction liquor, the immersion liquid of Poria cocos temperature and the tuber of pinellia are extracted into the ethanol extract, distillation and rhizoma zingiberis obtains
Mixed soaking solution is sufficiently mixed, and is concentrated into density and is the paste of 1.10-1.20, and the extract of licorice root of formula ratio is added,
The paste is mixed with the extract of licorice root and recycled ethyl alcohol, the Pogostemon cablin of auxiliary material Tween 80 and the formula ratio is added
The aqueous medium of oil, the mixed liquor of perilla leaf oil and surplus adjusts pH value to 5.8-6.2 with sodium hydroxide, obtains the Chinese traditional medicine composition
Object.
3. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucosa injury associated diseases,
It is characterized in that, the drug of the treatment mucosa injury can be any pharmaceutically acceptable dosage form.
4. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucosa injury associated diseases,
It is characterized in that, the drug of the preparation treatment mucosa injury further includes pharmaceutical acceptable carrier and/or auxiliary agent.
5. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucosa injury associated diseases,
It is characterized in that, the drug of the preparation treatment mucosa injury further includes other active components.
6. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucosa injury associated diseases,
It is characterized in that, the mucous membrane includes gastric mucosa, oral mucosa or Colon and rectum mucous membrane.
7. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucosa injury associated diseases,
Be characterized in that, the disease is stomatitis or canker sore caused by oral mucosa lesion, gastritis caused by gastric mucosa damage, erosion or
Ulcer, colitis caused by Colon and rectum mucosa injury.
8. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucous membrane associated diseases, feature
It is, the disease is that mucosa injury is pain caused.
9. application of the Chinese medicine composition as claimed in claim 1 or 2 in the drug of preparation treatment mucous membrane associated diseases, feature
It is, the disease is skin lesion pain or bleeding caused by mucosa injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910017614.3A CN109453280A (en) | 2019-01-07 | 2019-01-07 | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910017614.3A CN109453280A (en) | 2019-01-07 | 2019-01-07 | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109453280A true CN109453280A (en) | 2019-03-12 |
Family
ID=65616308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910017614.3A Pending CN109453280A (en) | 2019-01-07 | 2019-01-07 | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453280A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112370522A (en) * | 2020-12-11 | 2021-02-19 | 张旭东 | Jianyu decoction for treating stomach diseases and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037790A1 (en) * | 2002-08-23 | 2004-02-26 | Shuji Watanabe | Oral composition, method of making the oral composition and oral hygiene method in japanese and chinese herbal remedy |
| CN1785419A (en) * | 2005-07-28 | 2006-06-14 | 江西汇仁药业有限公司 | Agastachel patchouli qi-righting fast dispersion solid preparation and its preparation method |
| CN102614335A (en) * | 2011-01-28 | 2012-08-01 | 北京亚东生物制药有限公司 | Method for preparing Huoxiang Zhengqi oral liquid |
| CN108938864A (en) * | 2018-06-19 | 2018-12-07 | 重庆太极实业（集团）股份有限公司 | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases |
-
2019
- 2019-01-07 CN CN201910017614.3A patent/CN109453280A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040037790A1 (en) * | 2002-08-23 | 2004-02-26 | Shuji Watanabe | Oral composition, method of making the oral composition and oral hygiene method in japanese and chinese herbal remedy |
| CN1785419A (en) * | 2005-07-28 | 2006-06-14 | 江西汇仁药业有限公司 | Agastachel patchouli qi-righting fast dispersion solid preparation and its preparation method |
| CN102614335A (en) * | 2011-01-28 | 2012-08-01 | 北京亚东生物制药有限公司 | Method for preparing Huoxiang Zhengqi oral liquid |
| CN108938864A (en) * | 2018-06-19 | 2018-12-07 | 重庆太极实业（集团）股份有限公司 | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases |
Non-Patent Citations (4)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典2010版第二增补本》", 30 September 2013, 中国医药科技出版社 * |
| 王春丽: "《中药方剂学基础》", 31 August 2013, 华东理工大学出版 * |
| 胡旭涛等: "藿香正气水的质量标准的研究 ", 《当代医学》 * |
| 邱德文: "《现代方剂学》", 31 October 2006, 中医古籍出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112370522A (en) * | 2020-12-11 | 2021-02-19 | 张旭东 | Jianyu decoction for treating stomach diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107789340B (en) | Solution preparation for andrographis paniculata aerosol inhalation and preparation method thereof | |
| CN102525871A (en) | Toothpaste for preventing and treating recurrent aphtha and preparation method | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN109453280A (en) | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases | |
| CN108938864A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases | |
| CN101647885B (en) | Medicine composition for treating coughs | |
| CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| WO2022047729A1 (en) | Anti-diarrheal suppository traditional chinese medicine composition, and preparation method therefor and use thereof | |
| CN103585515A (en) | Effervescing agent medicament for treating children alimentary anemia | |
| CN109568463A (en) | A kind of Antidiarrheal Chinese medicine composition and its preparation method and application | |
| CN1237994C (en) | Medicine composition for preparing canker and preparing method thereof | |
| CN110025705A (en) | A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN109498728A (en) | A kind of antimycotic Chinese medicine composition and its preparation method and application | |
| CN110075198A (en) | A kind of Chinese medicine composition and its preparation method and application for treating tonsillitis | |
| CN110090259A (en) | A kind of Chinese medicine composition and its preparation method and application for preventing and treating alimentary canal discomfort after drinking | |
| CN110075199A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN104435068B (en) | A kind of Cortex Eucommiae compositions and preparation thereof with antiobesity action | |
| CN115317577B (en) | Traditional Chinese medicine composition for treating children cough | |
| CN110075197A (en) | A kind of Chinese medicine composition that treating herpangina and its preparation and application | |
| CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer | |
| CN102526387A (en) | Medicinal composition for treating early-stage diabetic foot and preparation method thereof | |
| CN1985910A (en) | Plaster for treating constipation and its preparing method | |
| CN108175818B (en) | Traditional Chinese medicine composition for treating glaucoma and preparation method and application thereof | |
| CN1706464A (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190312 |
|
| RJ01 | Rejection of invention patent application after publication |